Professor Robert Rintoul
Professor of Thoracic Oncology and Honorary Consultant Respiratory Physician
Robert Rintoul is Professor of Thoracic Oncology in the Department of Oncology, University of Cambridge and Honorary Consultant Respiratory Physician, Royal Papworth Hospital. He qualified in medicine from the University of Edinburgh having undertaken his pre-clinical training at the University of St Andrews. He subsequently trained in respiratory medicine in London and Edinburgh receiving his doctorate from the University of Edinburgh for research investigating mechanisms underlying resistance to chemotherapy in small cell lung cancer.
He was appointed consultant in respiratory medicine specialising in thoracic oncology at Royal Papworth Hospital in 2005 before moving to the University of Cambridge in 2017. Prof Rintoul is co-lead of the Thoracic Cancer Programme of the Cancer Research UK Cambridge Cancer Centre and Director of the Papworth Trials Unit Collaboration, a UKCRC registered clinical trials unit. Since 2021 he has been the clinical lead of the Clinical Advisory Group of the UK Lung Cancer Coalition and joined the Board of Directors in 2023. Since 2023 he has been clinical director for the Cambridgeshire and Peterborough lung cancer screening programme.
Prof Rintoul runs programmes of research in early-stage lung cancer and pleural mesothelioma. In lung cancer his work is predominantly focussed on translational clinical trials in biomarker discovery for early detection of primary and second primary lung cancer. In 2014 he founded Mesobank UK, the UK national bioresource for malignant mesothelioma (www.mesobank.com) which is also developing and characterising novel organoid models. His research is funded by NIHR Cambridge Biomedical Research Centre, Cancer Research UK, Medical Research Council and Asthma and Lung UK.
He was appointed consultant in respiratory medicine specialising in thoracic oncology at Royal Papworth Hospital in 2005 before moving to the University of Cambridge in 2017. Prof Rintoul is co-lead of the Thoracic Cancer Programme of the Cancer Research UK Cambridge Cancer Centre and Director of the Papworth Trials Unit Collaboration, a UKCRC registered clinical trials unit. Since 2021 he has been the clinical lead of the Clinical Advisory Group of the UK Lung Cancer Coalition and joined the Board of Directors in 2023. Since 2023 he has been clinical director for the Cambridgeshire and Peterborough lung cancer screening programme.
Prof Rintoul runs programmes of research in early-stage lung cancer and pleural mesothelioma. In lung cancer his work is predominantly focussed on translational clinical trials in biomarker discovery for early detection of primary and second primary lung cancer. In 2014 he founded Mesobank UK, the UK national bioresource for malignant mesothelioma (www.mesobank.com) which is also developing and characterising novel organoid models. His research is funded by NIHR Cambridge Biomedical Research Centre, Cancer Research UK, Medical Research Council and Asthma and Lung UK.